New data for management of hepatocellular carcinoma
The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration
Encouraging results with sintilimab combination therapy in EGFR-mutated non-squamous NSCLC
In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting
IMpower010 and DESTINY-Lung01 are likely to change clinical practice in Asia
However, regulatory and financial issues will shape when and where this happens
What is the impact of first-line nivolumab on subsequent therapy choices for metastatic gastric cancer?
Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
Should renal cell carcinomas be managed differently in Asia?
The Pan-Asian adaptation of the ESMO guidelines introduces some changes to the standard of care in Europe, including diagnostic tests and the use of cytoreductive nephrectomy
Genetics and availability of treatments influence the management of head and neck cancer in Asia
The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021
Tailoring the management of localised colon cancer to the Asian population
Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
Do biosimilars improve access to oncology medicines in Asia?
Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access
How can quantifying the burden of rare cancers in Asia improve patient outcomes?
National cancer control programmes, pharmaceutical company interest and facilitation of clinical trial participation may be stimulated by epidemiological data